J C van den Bergen1, B H Wokke1, A A Janson2, S G van Duinen3, M A Hulsker4, H B Ginjaar5, J C van Deutekom2, A Aartsma-Rus4, H E Kan6, J J Verschuuren1. 1. Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands. 2. Prosensa Therapeutics B.V., Leiden, The Netherlands. 3. Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. 4. Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands. 5. Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands. 6. Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
Abstract
OBJECTIVE: Becker muscular dystrophy (BMD) is characterised by broad clinical variability. Ongoing studies exploring dystrophin restoration in Duchenne muscular dystrophy ask for better understanding of the relation between dystrophin levels and disease severity. We studied this relation in BMD patients with varying mutations, including a large subset with an exon 45-47 deletion. METHODS: Dystrophin was quantified by western blot analyses in a fresh muscle biopsy of the anterior tibial muscle. Disease severity was assessed using quantitative muscle strength measurements and functional disability scoring. MRI of the leg was performed in a subgroup to detect fatty infiltration. RESULTS: 33 BMD patients participated. No linear relation was found between dystrophin levels (range 3%-78%) and muscle strength or age at different disease milestones, in both the whole group and the subgroup of exon 45-47 deleted patients. However, patients with less than 10% dystrophin all showed a severe disease course. No relation was found between disease severity and age when analysing the whole group. By contrast, in the exon 45-47 deleted subgroup, muscle strength and levels of fatty infiltration were significantly correlated with patients' age. CONCLUSIONS: Our study shows that dystrophin levels appear not to be a major determinant of disease severity in BMD, as long as it is above approximately 10%. A significant relation between age and disease course was only found in the exon 45-47 deletion subgroup. This suggests that at higher dystrophin levels, the disease course depends more on the mutation site than on the amount of the dystrophin protein produced. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE:Becker muscular dystrophy (BMD) is characterised by broad clinical variability. Ongoing studies exploring dystrophin restoration in Duchenne muscular dystrophy ask for better understanding of the relation between dystrophin levels and disease severity. We studied this relation in BMDpatients with varying mutations, including a large subset with an exon 45-47 deletion. METHODS:Dystrophin was quantified by western blot analyses in a fresh muscle biopsy of the anterior tibial muscle. Disease severity was assessed using quantitative muscle strength measurements and functional disability scoring. MRI of the leg was performed in a subgroup to detect fatty infiltration. RESULTS: 33 BMDpatients participated. No linear relation was found between dystrophin levels (range 3%-78%) and muscle strength or age at different disease milestones, in both the whole group and the subgroup of exon 45-47 deleted patients. However, patients with less than 10% dystrophin all showed a severe disease course. No relation was found between disease severity and age when analysing the whole group. By contrast, in the exon 45-47 deleted subgroup, muscle strength and levels of fatty infiltration were significantly correlated with patients' age. CONCLUSIONS: Our study shows that dystrophin levels appear not to be a major determinant of disease severity in BMD, as long as it is above approximately 10%. A significant relation between age and disease course was only found in the exon 45-47 deletion subgroup. This suggests that at higher dystrophin levels, the disease course depends more on the mutation site than on the amount of the dystrophin protein produced. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Vivek Kalia; Doris G Leung; Darryl B Sneag; Filippo Del Grande; John A Carrino Journal: Semin Musculoskelet Radiol Date: 2017-08-03 Impact factor: 1.777
Authors: Utkarsh J Dang; Michael Ziemba; Paula R Clemens; Yetrib Hathout; Laurie S Conklin; Eric P Hoffman Journal: Hum Mol Genet Date: 2020-08-29 Impact factor: 6.150
Authors: Jennifer G Andrews; Molly M Lamb; Kristin Conway; Natalie Street; Christina Westfield; Emma Ciafaloni; Dennis Matthews; Christopher Cunniff; Shree Pandya; Deborah J Fox Journal: J Neuromuscul Dis Date: 2018
Authors: Elizabeth M Gibbs; Florian Barthélémy; Emilie D Douine; Natalie C Hardiman; Perry B Shieh; Negar Khanlou; Rachelle H Crosbie; Stanley F Nelson; M Carrie Miceli Journal: Neuromuscul Disord Date: 2019-09-24 Impact factor: 4.296